Pregled bibliografske jedinice broj: 1170363
EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations
EUROmediCAT signal detection: an evaluation of selected congenital anomaly‐medication associations // British Journal of Clinical Pharmacology, 82 (2016), 4; 1094-1109 doi:10.1111/bcp.12947 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1170363 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
EUROmediCAT signal detection: an evaluation of selected congenital
anomaly‐medication associations
Autori
Given, Joanne E. ; Loane, Maria ; Luteijn, Johannes M. ; Morris, Joan K. ; Jong van den Berg, Lolkje T.W. ; Garne, Ester ; Addor, Marie‐Claude ; Barisic, Ingeborg ; Walle, Hermien ; Gatt, Miriam ; Klungsoyr, Kari ; Khoshnood, Babak ; Latos‐Bielenska, Anna ; Nelen, Vera ; Neville, Amanda J. ; O'Mahony, Mary ; Pierini, Anna ; Tucker, David ; Wiesel, Awi ; Dolk, Helen
Izvornik
British Journal of Clinical Pharmacology (0306-5251) 82
(2016), 4;
1094-1109
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
congenital anomalies ; drug-induced anomalies ; pharmacoepidemiology ; pharmacovigilance ; pregnancy ; signal evaluation.
Sažetak
Aims: To evaluate congenital anomaly (CA)-medication exposure associations produced by the new EUROmediCAT signal detection system and determine which require further investigation. Methods: Data from 15 EUROCAT registries (1995-2011) with medication exposures at the chemical substance (5th level of Anatomic Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human teratogenicity. Results: Thirteen out of 27 CA-medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70-8.53 ; congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99-14.20/OR 28.20, 95% CI 4.63-122.24) ; complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70-22.93) ; hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10- 1.76) ; hypospadias and synthetic ovulation stimulants (OR 1.89, 95% CI 1.28-2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk-forming laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists. Conclusion: Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to confirm the remaining signals. Some chance associations are expected and confounding by indication is possible.
Izvorni jezik
Engleski
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE